Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Blood (2014) 123 (21): 3247–3254.

https://doi.org/10.1182/blood-2014-01-546150

Published: 2014

Includes: Supplemental data

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial

Johannes Bloehdorn, MD, Martin Sill, PhD, Christian Langer, MD, Axel Benner, Dipl.Stat., Thorsten Zenz, MD, Andreas Bühler, MD, Raymonde Busch, PhD, Peter Dreger, MD, Ulrich Jäger, MD, Michael Hallek, M.D. Ph.D., Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1618.

https://doi.org/10.1182/blood.V122.21.1618.1618

Published: 2013

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Andrea Schnaiter, Peter Paschka, Marianna Rossi, Thorsten Zenz, Andreas Bühler, Dirk Winkler, Mario Cazzola, Konstanze Döhner, Jennifer Edelmann, Daniel Mertens, Sabrina Kless, Silja Mack, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2013) 122 (7): 1266–1270.

https://doi.org/10.1182/blood-2013-03-488197

Published: 2013

Includes: Supplemental data

Journal Articles

Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells

Carsten Zwick, Natalie Fadle, Evi Regitz, Maria Kemele, Stephan Stilgenbauer, Andreas Bühler, Michael Pfreundschuh, Klaus-Dieter Preuss

Blood (2013) 121 (23): 4708–4717.

https://doi.org/10.1182/blood-2012-08-447904

Published: 2013

Includes: Supplemental data

Journal Articles

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Blood (2013) 121 (16): 3284–3288.

https://doi.org/10.1182/blood-2012-11-469627

Published: 2013

Includes: Supplemental data

Journal Articles

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Blood (2012) 120 (24): 4783–4794.

https://doi.org/10.1182/blood-2012-04-423517

Published: 2012

Includes: Supplemental data

Journal Articles

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Blood (2012) 119 (21): 4851–4859.

https://doi.org/10.1182/blood-2011-09-378505

Published: 2012

Includes: Supplemental data

Journal Articles

DNA damage–induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing

Julia Mohr, Hanne Helfrich, Maxi Fuge, Eric Eldering, Andreas Bühler, Dirk Winkler, Matthias Volden, Arnon P. Kater, Daniel Mertens, Doreen Te Raa, Hartmut Döhner, Stephan Stilgenbauer, Thorsten Zenz

Blood (2011) 117 (5): 1622–1632.

https://doi.org/10.1182/blood-2010-08-300160

Published: 2011

Includes: Supplemental data

Journal Articles

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

Thorsten Zenz, Sonja Häbe, Tina Denzel, Julia Mohr, Dirk Winkler, Andreas Bühler, Antonio Sarno, Silja Groner, Daniel Mertens, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (13): 2589–2597.

https://doi.org/10.1182/blood-2009-05-224071

Published: 2009

Includes: Supplemental data

Journal Articles

miR-34a as part of the resistance network in chronic lymphocytic leukemia

Thorsten Zenz, Julia Mohr, Eric Eldering, Arnon P. Kater, Andreas Bühler, Dirk Kienle, Dirk Winkler, Jan Dürig, Marinus H. J. van Oers, Daniel Mertens, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 113 (16): 3801–3808.

https://doi.org/10.1182/blood-2008-08-172254

Published: 2009

Includes: Supplemental data

Journal Articles

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

Thorsten Zenz, Alexander Kröber, Katrin Scherer, Sonja Häbe, Andreas Bühler, Axel Benner, Tina Denzel, Dirk Winkler, Jennifer Edelmann, Carsten Schwänen, Hartmut Döhner, Stephan Stilgenbauer

Blood (2008) 112 (8): 3322–3329.

https://doi.org/10.1182/blood-2008-04-154070

Published: 2008

Journal Articles

Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia

Göran Roos, Alexander Kröber, Pawel Grabowski, Dirk Kienle, Andreas Bühler, Hartmut Döhner, Richard Rosenquist, Stephan Stilgenbauer

Blood (2008) 111 (4): 2246–2252.

https://doi.org/10.1182/blood-2007-05-092759

Published: 2008

Journal Articles

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Krzysztof Giannopoulos, MD, PhD, Andreas Buhler, MD, PhD, Jinfei Chen, MD, PhD, Alexander Krober, MD, PhD, Malgorzata Kowal, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD, Jochen Greiner, MD, PhD, Hartmut Dohner, MD, PhD, Stephan Stilgenbauer, MD, PhD, Michael Schmitt, MD, PhD

Blood (2007) 110 (11): 2051.

https://doi.org/10.1182/blood.V110.11.2051.2051

Published: 2007

Journal Articles

Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in V H 3-21-Utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Status.

Fiona Murray, Mia Thorselius, Alexander Krober, Ulf Thunberg, Gerard Tobin, Andreas Buhler, Dirk Kienle, Emilia Albesiano, Lan-Phuong Dao-Ung, James Wiley, Juhani Vilpo, Anna Laurell, Goran Roos, Karin Karlsson, Nicholas Chiorazzi, Roberto Marasca, Hartmut Dohner, Stephan Stilgenbauer, Richard Rosenquist

Blood (2005) 106 (11): 175.

https://doi.org/10.1182/blood.V106.11.175.175

Published: 2005

NARROW

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

DNA damage–induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

miR-34a as part of the resistance network in chronic lymphocytic leukemia

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in V H 3-21-Utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only